Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Debt / NOTE 1.250% 5/1
-
Number of holders
-
28
-
Total 13F principal, excl. options
-
244M
-
Principal change
-
+244M
-
Total reported value, excl. options
-
$247M
-
Value change
-
+$247M
-
Number of buys
-
28
-
Price
-
$1.00
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2021
29 filings reported holding 09061GAK7 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q2 2021.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 has 28 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $244M of principal
.
Largest 10 bondholders include ADVENT CAPITAL MANAGEMENT /DE/ ($70.7M of principal), MACKAY SHIELDS LLC ($24.5M of principal), UBS ASSET MANAGEMENT AMERICAS INC ($23M of principal), CNH PARTNERS LLC ($21.7M of principal), DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main ($15.7M of principal), STATE STREET CORP ($15.3M of principal), SHENKMAN CAPITAL MANAGEMENT INC ($14.8M of principal), LAZARD ASSET MANAGEMENT LLC ($14.2M of principal), DEUTSCHE BANK AG\ ($8.81M of principal), and NEW YORK STATE COMMON RETIREMENT FUND ($7.59M of principal).
This table shows the top 28 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.